NCT06007937View on ClinicalTrials.gov

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

August 17, 2028

Study Completion Date

August 17, 2028

Conditions
Non Small Cell Lung CancerMetastaticRecurrent
Interventions
DRUG

Lorlatinib

Lorlatinib 100 mg orally daily

DRUG

Ramucirumab

Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.

Trial Locations (6)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison

11570

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER